Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains... see more

Recent & Breaking News (NDAQ:COLL)

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire 2 days ago

Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory

GlobeNewswire March 19, 2026

Collegium to Present New Real-World Data at PainConnect 2026

GlobeNewswire March 5, 2026

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community

GlobeNewswire March 3, 2026

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire March 2, 2026

Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results

GlobeNewswire February 26, 2026

Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical

GlobeNewswire February 23, 2026

Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026

GlobeNewswire February 12, 2026

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

GlobeNewswire January 15, 2026

Collegium Provides 2026 Financial Guidance and Business Update

GlobeNewswire January 8, 2026

Collegium Announces the Closing of $980 Million Syndicated Credit Facility

GlobeNewswire December 30, 2025

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire November 12, 2025

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

GlobeNewswire November 6, 2025

Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada

GlobeNewswire October 30, 2025

Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment

GlobeNewswire October 29, 2025

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire October 23, 2025

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

GlobeNewswire October 22, 2025

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

GlobeNewswire October 13, 2025

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2025

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting

GlobeNewswire August 25, 2025

Podcasts